{{How did such a disparity come about? (I know the history with respect to SLXP and Ono Pharmaceutical.)}}
Dew, I previously wrote 50%-%-60% of global (ex-US) sales. I checked it and the PGNX press release says 60% of revenues SLXP receives from ex-US sublicensees of Relistor, which is not the same as 60% of world wide revenues since obviously the sublicensee would get a nice cut. The payment percentages can be found in the link. Sorry for my error and for any confusion it might have caused.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.